
|Videos|February 3, 2022
Dr. Kim and Dr. Kapur on the “disconnect” between exploring and receiving therapy for OAB
Author(s)Urology Times staff
“I think there's a disconnect between the patients saying they're interested in these therapies, and the patients that actually go on to [receive] them,” says Jason Kim, MD.
Advertisement
In this video, Anjali Kapur, MD, and Jason Kim, MD, discuss the takeaways of the study, “Patient preference of third line therapy for overactive bladder,” which will be presented at the Society of Women in Urology Annual Clinical Mentoring Conference. Kapur is a PGY-4 resident and Kim is an associate professor of urology, director of the Women’s Pelvic Health and Continence Center, and urology residency program director at Stony Brook Medicine in East Setauket, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












